NurExone Biologic Secures C$2.3 Million Funding for U.S. Expansion and Uplisting Plans

NurExone Biologic ( (TSE:NRX) ) has provided an update.

NurExone Biologic Inc. has announced the successful closure of a C$2.3 million private placement, with plans to use the proceeds for working capital, establishing a U.S. production facility, and pursuing an uplisting to a major U.S. exchange. This financing marks a significant milestone for the company, enhancing its operational footprint and financial position, and aligning with its long-term growth objectives in the regenerative medicine sector.

More about NurExone Biologic

NurExone Biologic Inc. is a biotech company listed on TSXV, OTCQB, and Frankfurt exchanges, focusing on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has shown promising preclinical results for treating acute spinal cord and optic nerve injuries, targeting multi-billion-dollar markets. The company is also involved in providing quality exosomes and minimally invasive delivery systems for various indications, with a U.S. subsidiary, Exo-Top Inc., to support its North American growth strategy.

YTD Price Performance: 9.84%

Average Trading Volume: 34,223

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$37.4M

See more data about NRX stock on TipRanks’ Stock Analysis page.